Roche Diagnostics reported a 3% revenue decline in the first half of 2025, mainly driven by volume-based procurement and healthcare pricing reforms in China, which caused a 26% sales drop there. Excluding China, the Diagnostics division's revenues rose 6% year-over-year. Core labs and immunodiagnostics saw declines, whereas clinical chemistry and pathology labs grew. Despite challenges, Roche's overall sales increased 4%, with net income rising to CHF 7.83 billion. The company confirmed guidance for mid-single-digit percentage growth at constant rates for the full year.